THE FIRST JUDGMENT OF THE PRIMARY JUDGE
29 After introducing the parties and generally describing their products, at [31]-[40] (pp 132-134), the primary judge summarised RLA's claims, the appellant's defences to those claims and the issues arising for consideration and determination by him. His Honour observed that RLA alleged that each of Clewlow, Sofat and Nixon owed both a contractual and equitable duty of confidence to RLA arising from the terms of their respective contracts of employment and the relationship of employment which each of them had with RLA. Each of Clewlow, Sofat and Nixon admitted that they owed duties of confidentiality to RLA. Next, RLA alleged that the formulations and processes for manufacturing each of PE 265 and Roberts 656 were confidential information of RLA and also trade secrets of RLA. It was then alleged that, in breach of their duties of confidence, each of Clewlow, Sofat and Nixon disclosed to each other and to Nexus certain confidential information which was the property of RLA which Nexus then used to bring Nexus 820 (and indeed Nexus 840) to the market much sooner than would have occurred had the appellants not misused RLA's confidential information. RLA alleged that Nexus used RLA's confidential information as a springboard to bring its products to market in a shorter timeframe than would otherwise have been the case and in direct competition with those of RLA.
30 RLA also alleged that the appellants had been guilty of misleading and deceptive conduct or conduct which was likely to mislead or deceive in contravention of s 52 of the Trade Practices Act 1974 (Cth) (the Trade Practices Act) and its cognate State provisions by representing to consumers that Nexus 820 and Nexus 840 had been developed by Nexus. It was also alleged that the appellants had breached s 53(c) of the Trade Practices Act and the cognate State legislative provisions.
31 At [40] (p 134), the primary judge said that the two matters in dispute between the parties were:
(a) Whether the information which RLA claimed was both confidential and a trade secret truly bore that status; and, if so,
(b) Whether the appellants misused that information in developing either or both Nexus 820 and Nexus 840.
32 At [42]-[75] (pp 135-146) of the first judgment, his Honour then discussed the relevant legal principles as to what is confidential information and a trade secret and then considered those principles in the context of the present case.
33 At [45]-[47] (pp 137-138), the primary judge found that the description of RLA's confidential information given by RLA in the latest iteration of its Statement of Claim at [10] of that pleading was sufficient to capture as a subset of the specified confidential information:
… the type, relative proportions and number of polymers specified in the formulas for PE 265 and Roberts 656.
34 That finding led to the rejection of a submission made by the appellants to his Honour that the description of the confidential information in RLA's Statement of Claim was too wide with the consequence that confidential or trade secret status should not be allowed to individual ingredients in PE 265 and Roberts 656.
35 His Honour accepted at [47] (p 138) that this quality of confidence attached to the information even though the individual ingredients constituting, inter alia, PE 265, were readily available from industry suppliers. One such supplier was BASF which supplied "starting point formulations" (SPFs) for particular polymers to the appellants and Nexus. His Honour found, at [50] (p 139), on the evidence before him that, although SPFs may contribute to the ultimate production of an adhesive, significant further development is usually required.
36 Moreover, his Honour found at [52] (p 139) that, although it would have been possible to independently ascertain the confidential information involved in the manufacture of PE 265, this would require the expenditure of time, effort and money, such that the information could not be said to be in the public domain.
37 His Honour went on to hold that RLA's confidential information was both confidential and a trade secret. In particular, at [62] (p 142) of the first judgment, his Honour held that the number, type and amount of polymers in both PE 265 and Roberts 656 constitute a trade secret. At [62]-[64] (pp 142-143), his Honour said:
62 It is, in my view, quite clear from the evidence that each of Clewlow, Sofat and Nixon, in fact, knew that the confidential information was confidential to RLA in the context of the adhesives industry. In accordance with the principles enunciated in Australian Medic-Care and GlaxoSmithKline, I consider the confidential information to have the "necessary quality of confidence about it" to import an obligation of confidence enforceable by an action like the present. I have also been led to characterise the confidential information, and certain specific items of that information, as a "trade secret". I do not accept that certain aspects of the confidential information, such as the number, type and amount of polymers in a formulation, can be considered part of an employee's "stock of knowledge" which can legitimately be drawn upon when working for a new employer. As indicated at [59] above, the "know-how" exemption does not apply where the knowledge constitutes a "trade secret", which in this case comprises specific items of the confidential information that can fairly be regarded as a separate part of an employee's stock of knowledge but which "a person of ordinary honesty and intelligence would recognise to be the property of his old employer". Accordingly, for the reasons explained in the following paragraph, I consider that the number, type and amount of polymers in both PE 265 and Roberts 656 constitute a "trade secret".
63 In these proceedings, both parties acknowledged that the key components of the adhesive products PE 265, Roberts 656, Nexus 820 and Nexus 840, are acrylic polymers. The polymer content of each adhesive makes up of the bulk of the raw material used in both pressure sensitive adhesives and vinyl flooring adhesives and is considered to be the main "cost driver" as it is the most expensive ingredient in the finished product. In my view, any knowledge of the type, number and quantity (that is, weight) of polymer used in a specific adhesive formulation constitutes a "trade secret", provided that the information is not in the public domain. Accordingly, any "stock of knowledge" taken away by the respondents on leaving RLA, which included such information about the polymers used in PE 265 and Roberts 656, was a "trade secret", and not available to be used to further the development of a competitive product. Although such knowledge might have formed a separate part of an employee's stock of knowledge it was, nevertheless, information which "a person of ordinary honesty and intelligence would recognise to be the property of his old employer".
64 In the interests of maintaining the confidentiality of information possessed by both parties, I shall identify the ingredients used in each product with a particular pseudonym. It is clear that the parties regard the polymers as the main constituent of their respective adhesives. Where necessary later in these reasons, I shall assign other pseudonyms to other ingredients. Accordingly, the two polymers in PE 265 are hereafter referred to as Polymer A and Polymer B. The polymer in Roberts 656 is Polymer B. The polymers in Nexus 820 are Polymer 1, Polymer 2 and Polymer A. The polymers in Nexus 840 are Polymer B and Polymer 3. I shall also make reference to a Nuplex Polymer 4 and a Nuplex Polymer 5, which were considered in the development process by the respondents but ultimately not used in their final formula for Nexus 820 or Nexus 840.
38 His Honour concluded that, given the considerable amount of time, effort and resources put in to the development of PE 265 (and Roberts 656) by RLA and given the obvious importance to RLA of the formulation and manufacturing processes of those two products, they bore the necessary confidential quality. His Honour also found that RLA had taken steps to preserve the confidentiality of its confidential information.
39 His Honour concluded (at [66] (p 143) of the first judgment) that each of Clewlow, Sofat and Nixon owed both a contractual and an equitable duty of confidence to RLA, arising out of their employment contracts with RLA and out of the employment relationship itself. Each was under a duty not to use or to disclose any of the confidential information which he or she had retained once he or she had left the employment of RLA.
40 At [67]-[69] (pp 144-145), his Honour went on to say:
67 During the course of his or her employment, each of the respondents had access to the confidential information and, in particular, to System 21 which contained the product formulations for PE 265 and Roberts 656. Further, the evidence before the court in the form of witness statements of the respondents and their oral evidence under cross-examination indicates that each of them acquired confidential information in the sense of being exposed to it during the employment and retaining knowledge of it after leaving. This is evident from the following:
(a) In his witness statement, Clewlow claimed that, while employed at RLA, he "had access to many if not all of the RLA formulations. I also had intimate knowledge of the PE 265 and R 656 formulations, but from a costing point of view only". Clewlow affirmed this assertion during cross-examination.
(b) In her first witness statement, Sofat claimed that she had acquired knowledge of the two polymers used in PE 265 from her "stock taking days at RLA", where she came into contact with the Flooring Adhesive shed which contained large storage tanks for the two polymers used in PE 265. Further, she explained in her first witness statement that, when she started developing Nexus 820, she had been "aware of the raw materials and polymers used in PE 265", though she did not know their specific quantities. Under cross-examination she confirmed her possession of this knowledge.
(c) During cross-examination Nixon conceded that he knew most of the ingredients in Roberts 656 and PE 265 and his answers to Mr Derham's questioning seemed to suggest that he had some knowledge of specific quantities. Nixon admitted, in his witness statement of 4 September 2009, that, while working for Nexus Adhesives he had found an old notebook from his employment with RLA which contained some notes about "items and quantities contained in the PE265 adhesive product". He claimed that he had mentioned what was contained in his old notebook "in passing" to Sofat. Sofat claimed in her first witness statement that it had been Nixon who had told her of the two polymers in PE 265 and their proportions when he joined Nexus, and that she had written these in her notebook (notebook).
68 It is also clear from the evidence that the respondents had disclosed the retained knowledge described at [67] above to each other. In RLA's submission, in breach of their duty of confidence they thereby authorised and encouraged its use when developing adhesives for Nexus Adhesives. The evidence supporting a finding to that effect is as follows:
(a) Sofat gave evidence during cross-examination that she was aware of Clewlow's knowledge of the formulations for PE 265 and Roberts 656 and that Clewlow had "encouraged" her to try out, as part of her development process, what he remembered to be the key polymer ingredients in PE 265, in their approximate proportions.
(b) As mentioned at [66] above, Nixon also conceded that he had shared with Sofat the information regarding the polymers in PE 265, as well as their proportions and cost.
(c) Sofat conceded that she had transcribed into her notebook on two separate occasions what Nixon had told her about the ingredients in PE 265. It appears from Sofat's first witness statement that Nixon had provided her at some stage in March 2007 with details of the PE 265 polymers, their proportion and cost, and then later, "on a date between 30 July 2007 and 28 August 2007 [I] was having a further conversation with Brett Nixon and he listed some further components of PE 265, which I wrote down in my note book".
69 On this evidence, at the least, the respondents have been in breach of their obligation under the terms of their respective contracts not to use or disclose to any third party either during or after their employment, trade secrets and information confidential to RLA. Under the principles enunciated in Australian Medic-Care, the agreed elements of the action for breach of confidence have been made out. However, for RLA to obtain the remedies which it seeks, it must make good its claim that the respondents' breaches of their duty of confidence have led to their disclosing and using their knowledge of the confidential information to bring to market competing adhesive products more quickly than would otherwise have been the case, effectively using that information as a "springboard" to develop their own products. Accordingly, there needs to be proof to the requisite standard that the respondents used the confidential information in that way and to that effect.
41 Clewlow, in particular, had intimate knowledge of costing information referable to the ingredients of PE 265 and Roberts 656. It appears that Nixon also had knowledge of costing. His duties at RLA were similar to that of Clewlow and Sofat gave evidence that he provided her with confidential information about the cost of the two crucial polymers (referred to at [27] (p 132) and [134] (p 164)).
42 At [70]-[75] (pp 145-146), his Honour set out the relevant principles in relation to the springboard doctrine.
43 At [76] (p 147), his Honour proceeded to address the question of whether the appellants had misused RLA's confidential information. At [76]-[78] (p 147), his Honour articulated the four potential broad inferences available to be drawn. At [79]-[80] (p 148), his Honour rejected what he described as "the ruse inference". In the end, his Honour rejected the proposition that the whole of the activity undertaken by Nexus in purporting independently to develop Nexus 820 and Nexus 840 had been a "ruse" to mask the unlawful use of RLA's confidential information. However, he found at [78] (p 147) and [99] (p 155) that, notwithstanding their desire to produce the adhesives independently, the respondents misused particular items of confidential information, namely the type, number and amount of polymers used by RLA, which constituted a trade secret, in the development of the Nexus products.
44 At [100]-[146] (pp 155-169), his Honour set out his reasons for concluding, as he did, that the appellants used parts of RLA's confidential information in numerous ways throughout the development process of Nexus 820. In this part of his Honour's judgment, his Honour found four particular misuses. The first misuse (dealt with at [102]-[108) (pp 155-157)), was that, right from the very start of the development process of Nexus 820, in late October 2006 or early November 2006, the formulation of PE 265 had been a reference point for Sofat's work. This first use led to a gradual incorporation of PE 265 technology into the formulation of Nexus 820.
45 His Honour's conclusion as to this use was based in large measure upon references to the formula for PE 265 in an exercise book maintained by Sofat when she was employed by RLA. One such reference was to a table set out in the exercise book and reproduced by the primary judge at [103] (pp 155-156). The learned primary judge went on to deal with this at [105]-[107] (p 156) as follows:
105 On the other hand, RLA contended, the formulation in the table at [103] above matches the formulation for PE 265 as it stood when Sofat left RLA. Evidence of the formulation for PE 265 at the time when Sofat left RLA confirms this contention. Even the specific brand of biocide used in the above formulation (not identified in these reasons) is identical to that used in PE 265. Accordingly, it is evident that Sofat's intention was to "try" a particular formulation using the same two acrylic polymers, gum rosin and biocide as were present in PE 265. This is claimed by RLA to be evidence of Sofat reinforcing what she knew, or had been told, of PE 265. This evidence tends to show that Sofat knew the PE 265 formula and was using it at this early "research stage" in the development of Nexus 820.
106 When confronted during cross-examination with this parallel between the exercise book formula and the PE 265 formula, Sofat accepted its existence and suggested that the reason for it "could have been" because she had noted the ingredients that she knew were in PE 265 as something to try while developing a vinyl sheet adhesive. When asked by Mr Derham QC why she had made those notes under the heading, "Try", her answer was simply "Why not?" RLA argues that this evidence establishes that, from the very start of the development process of Nexus 820, in late October 2006 or early November 2006, the formulation for PE 265 had been a reference point for Sofat's work. I accept this argument.
107 I am not satisfied that Sofat's explanation for reproducing in the exercise book the PE 265 formulation is sufficient to exclude as the preferable inference that the respondents did in fact use the confidential information. However, it seems to me that her evidence suggests that she did not comprehend, at that time, that she was using the confidential information illegitimately. As I have outlined above, the test being objective in nature, and it having been found that a reasonable person would understand such information to have been confidential, whether she knew that to use the confidential information as she did was impermissible is, for the purposes of liability at least, irrelevant. Sofat ought to have known that to use the confidential information to confer a possible competitive benefit on Nexus Adhesives was prohibited.
46 The second use dealt with by his Honour is addressed at [109]-[131] (pp 157-163).
47 It was RLA's submission to his Honour that the development process for Nexus 820 was driven by the appellant's desire to target, in particular, the RLA polymers used in PE 265 and Roberts 656 with a view to replacing them with what the appellants believed to be the Nuplex equivalent polymers. In this passage of the first judgment, his Honour considered the evidence of Sofat and how her testimony at trial measured up against the contents of her exercise book. His Honour observed at [111] (p 157) that the exercise book is replete with references to the polymers used in PE 265 including specific weights and relative proportions. One such reference was reproduced at [112] (p 158) and his Honour set out Sofat's evidence in cross-examination in which she said that Clewlow had encouraged her to try the different polymers, ie Polymer A and Polymer B, in her formulation.
48 At [113] (p 158) of the first judgment, his Honour said:
113 In my view, this evidence of Sofat under cross-examination supports the inference that, during Sofat's actual laboratory development of Nexus 820 at some point between 31 January 2007 and 26 March 2007, Clewlow disclosed to her the two polymers in PE 265 and their relative proportions and, as a result of that disclosure, the use which was then made of that part of the confidential information was to replace the BASF polymers contained in PE 265 (that is, Polymers A and B) with the Nuplex "equivalents" or "replacements". This inference becomes more compelling when one turns to the evidence of the utilisation of Polymer B.
49 At [114] (pp 158-159), his Honour found that there was no logical explanation for the use of Polymer B in a vinyl flooring adhesive unless the developer was intending to target a replacement polymer as submitted by RLA.
50 His Honour concluded that, from 31 January 2007, when Sofat began actively developing Nexus 820, Clewlow encouraged, and Sofat engaged in, the use of RLA's confidential information for the purpose of progressing the development of Nexus 820.
51 Importantly, his Honour found at [115] (p 159) that Sofat's answers to questions about why Polymer B was being considered were "not helpful" and were "somewhat evasive".
52 At [117]-[131] (pp 159-163), his Honour dealt with similar submissions directed to Nexus 840.
53 At [132] (p 164), his Honour said:
Other ingredients
132 When one has regard to ingredients other than the main polymers, there is insufficient evidence to support the inference that there was a simple targeting of the ingredients of Roberts 656 and substituting for them like or equivalent ingredients. Information about the ingredients of adhesives of the relevant type was readily available in the public domain, from the literature to the SPFs available from companies such as BASF and Nuplex. I also find that knowledge of the type of ingredients used in the relevant adhesives was part of the respondents' general stock of knowledge when they left RLA. Notwithstanding that finding, I consider that use of the specific types or brands of ingredients in the weights and relative percentages in which they were present in the RLA products would amount to a breach of confidence. The evidence does not enable me to impute that kind of use to the respondents. Nor do I make any finding against the respondents of misuse of confidential information in choosing any of the other ingredients in Nexus 820 and Nexus 840.
54 At [133]-[135] (pp 164-165), his Honour dealt with the third misuse of RLA's confidential information. In the course of dealing with that third use, his Honour recorded that, in Sofat's exercise book, there was a detailed transcription of the key polymers in PE 265 and their relative weights, including their dry weights (at [134] (p 164)). This entry, which was based in part on confidential costing information given to her by Nixon, allowed Sofat to determine the cost of the ingredients of PE 265.
55 At [135] (p 164-165), his Honour said:
… the costing of the constituent ingredients is critical in bringing an adhesive to market and, as both sides accept, the key ingredients in these adhesives were the polymers. Therefore, knowledge of the precise costs of the principal polymers in PE 265, when used as a comparator in developing a competing product, would, in my view, constitute a trade secret. Accordingly, I accept that the confidential information was misused by the respondents in order to establish "cost drivers" and aid in the development of Nexus 820. If the respondents had not possessed that information but had been compelled to undertake independent development and research from material in the public domain it is likely that the commercial development of Nexus 820, would have occupied more time and resources than it did. As a result, the entry on to the market of Nexus 820 would have been delayed, denying the respondents the "springboard" benefit which they achieved.
56 At [136]-[146] (pp 165-169), his Honour dealt with the fourth misuse of RLA's confidential information. His Honour found that the formulation of PE 265 was used to assist Nexus in solving what was described at trial as the "post thickening problem" which had become apparent in mid August 2007 but which was resolved by the end of September 2007.
57 Ultimately, Polymer A came to be used in Nexus 820 and was introduced at this time in order to deal with the post thickening problem. His Honour found that there was an irresistible inference that the formula PE 265 was studied and analysed with a view to ascertaining whether one of its important ingredients should be introduced into Nexus 820 in order to solve the post thickening problem.
58 At [143]-[145] (pp 168-169), his Honour said:
143 I regard as inadequate the respondents' explanation of their activities in relation to the confidential information. The inference I prefer is that Sofat and Nixon used the confidential information which Nixon had communicated to Sofat to compare the ingredients in PE 265 with those in Nexus 820 in an attempt to identify the cause of the "post thickening problem". That misuse of the confidential information led, ultimately, to the discovery that the problem could be overcome by adding Polymer A to the formulation of Nexus 820. How the addition of Polymer A was arrived at as the solution is unclear from the respondents' evidence. Sofat gave differing accounts of how Polymer A came to be used in Nexus 820, which RLA argued was indicative of her inability to make the facts accord with her version of events. Her first explanation has been set out at [137] of these reasons. In essence, she claimed that "at BASF's suggestion, [she] looked at incorporating [Polymer A] into the Nexus 820 formulation." RLA contended that her evidence in this respect should be given little or no weight because nobody from BASF had been called to corroborate it and no evidence had been adduced of the nature of Sofat's purported initial investigations into the suitability of using Polymer A. Nor, RLA claimed, was there evidence of the results of her later investigations of polymer combinations and the stability of the end product. Even if it be accepted that BASF had provided advice to try Polymer A, Sofat's reliance on that advice was said to be contradicted by her "Development Notes" which she provided to the respondents' solicitors and were later relied on by Mr Turner in his expert's report. There were two versions of the "Development Notes", one of which made no reference to how or why Sofat decided to use Polymer A in Nexus 820, while the other stated that:
Nuplex thought a small addition of V275 may assist. (As per Graham's report - discovery 58) - Attachment 9. As there was no lab sample availa[b]le, and BASF still had a complicates [sic] method of ordering samples, I took the decision to work with [Polymer A], stock of which I had in the lab and timing was crucial.
144 As RLA has argued, that explanation of why Sofat resorted to Polymer A is inconsistent with her witness statement. It is also contrary to the evidence of Dr Farquharson who recommended that Sofat should use Polymer 1 instead of V 275 and Polymer 4 instead of Polymer A.
145 Accordingly, I regard this aspect of Sofat's evidence as failing to explain how she came to include Polymer A in Nexus 820. Rather, I have found persuasive the transcription of the PE 265 ingredients into Sofat's notebook, the "batch" samples incorporating the precise polymers used in PE 265 and the other evidence in Sofat's notebook set out at [133] above. That being the available evidence, I prefer the inference that the respondents discovered, in the time that they did, that Polymer A was a solution to the "post thickening problem" because they were using the PE 265 formulation as a comparator. I reject Sofat's explanation as to how she resolved the "post thickening problem".
59 At [146] (p 169), his Honour said that he was reinforced in the conclusion which he had expressed at [145] (p 169) by the fact that there were no records showing a trial and error process in respect of other alleged solutions to the post thickening problem. His Honour also referred in this paragraph to the radical change in the formulation which came about by the introduction of Polymer A. Moreover, he referred to the commercial imperatives upon Nexus to find a solution. He said:
… although I accept that the respondents were under pressure to solve the "post-thickening problem", it would have been foolhardy to launch the reworked Nexus 820 on to the market without some certainty that the problem would not recur. Had Nexus 820 failed again, the damage to the reputation of Nexus Adhesives may well have been irreparable.
60 His Honour dealt at [147]-[151] (pp 169-170) with the effect of the expert evidence adduced by each party. He said that he had taken that evidence into account in making an assessment of how long independent development of adhesives like Nexus 820 should have taken.
61 He referred at [149] (p 170) to objections taken by the respondents at the trial to the admissibility of some parts of an expert's report relied upon by RLA. However, he said he had made his findings on liability without relying on the report. His Honour also said at [150] (p 170) that the parts of the report on which he relied were not the subject of objection and thus:
None of the respondents' objections affects my reliance on this information which, in any event, has been only peripheral to the central findings.
62 At [152]-[170] (pp 170-174), his Honour dealt with the impact of the springboard effect in the present case.
63 At [157] (p 171), his Honour said that he was satisfied that steps were taken to develop Nexus 820 as soon as Nexus was incorporated in August 2006. His Honour also found at that paragraph that physical production of trial batches did not occur before February 2007.
64 In these paragraphs of his Honour's first judgment, his Honour undertook a detailed analysis of the evidence, both lay and expert, directed to the question of springboard. He found at [165] (p 173) that, making the best use possible of the whole of the evidence, the period to be occupied in the independent development of a new adhesive was nine to twelve months.
65 At [169]-[170] (p 174), his Honour said:
169 In the light of the findings summarised above about the actual time taken to develop Nexus 820, I consider that the "research phase" of that process occupied approximately 1 month, during the period from late October 2006 until late February 2007. I further find that the "physical development phase" lasted for approximately 3 months, from the beginning of February 2007 to the beginning of May 2007 when the first commercial release of Nexus 820 occurred. In consequence, it probably took the respondents about 4 months in all to develop Nexus 820 and bring it to the market. That period is obviously well short of the nine to 12 months which I have postulated as the time frame in which a reasonably well-resourced producer could be expected to develop a new adhesive from "scratch" and launch it on the market. However, as I have found at [136] of these reasons, the respondents were first apprised of the "post thickening problem" in mid-August 2007. That problem was resolved in the space of a month, between late August 2007 and late September 2007. Accordingly, it is appropriate to add an extra month to the time imputed to the actual development of Nexus 820, making a total time of 5 months before the respondents achieved a marketable version of Nexus 820, at least 4 months and up to 7 months earlier than they would have had they not used the confidential information.
170 Although I regard the evidence canvassed earlier in these reasons as sufficient of itself to fix the respondents with liability for misuse of the confidential information, my findings in that respect derive additional support from the conclusion just explained, that the actual development of Nexus 820 occupied a period as short as only 5 months.
66 At [174] (p 175), his Honour determined that the springboard advantage comprised five and a half months. Ultimately, his Honour did not separately consider the claims under the Trade Practices Act and the State Fair Trading Acts.